

Special Issue

Targeted Therapy for Liver Metastases

Message from the Guest Editors

The unique vascular and anatomical structures of the liver create a favorable environment for metastatic cancer engraftment and survival, making secondary tumors the most frequently observed liver malignancies. Liver metastases are most commonly originating from colorectal cancer or generally the gastrointestinal tract, but almost half of patients affected by different cancer types will present with or eventually develop liver metastases. The liver oncological status is often a key determinant of patient prognosis, and the possibility of predicting, early diagnosing, and effectively treating liver metastases can significantly prolong survival. In recent decades, thanks to the increased knowledge of tumor and microenvironment biology and molecular profiles, targeted therapies have been developed and integrated into cancer treatment. This Special Issue will highlight all the possible roles of targeted therapy for liver metastases in all their diversity, covering all aspects that advance our understanding of such a complex oncological entity.

Guest Editors

Dr. Gianluca Rompianesi

Department of Clinical Medicine and Surgery, Federico II University Hospital, 80131 Naples, Italy

Dr. Jacopo Lanari

Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy

Deadline for manuscript submissions

1 November 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/230099

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)